In contrast, patients with HER2-enriched or triple-negative tumours, who show high pCR rates under contemporary regimens, may in the future represent candidates for omission of SLNB if additional evidence confirms a very low residual nodal burden in the context of negative AUS and breast pCR [27,28,29,30,31]. Here, ERBB2 is linked to neoplasm.